Collagen-derived markers of bone metabolism in osteogenesis imperfecta

Acta Paediatrica, International Journal of Paediatrics

Volumn 87, Issue 11, 1998, Pages 1131-1137

  Lund, A M ^a   Hansen, M ^a   Kollerup, G ^b   Juul, A ^a,c   Teisner, B ^d   Skovby, F ^a  

^a Rigshospitalet   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c Copenhagen Municipal Hospital ^*  (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Biochemical bone markers; Collagen; Collagen cross links; Osteogenesis imperfecta

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; OSTEOCALCIN; PROCOLLAGEN; PYRIDINIUM DERIVATIVE; PYRIDINOLINE;

ADOLESCENT; ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; BONE METABOLISM; CARBOXY TERMINAL SEQUENCE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; PRIORITY JOURNAL;

EID: 0031733390     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1651-2227.1998.tb00920.x     Document Type: Article

References (25)

1. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; 16: 101-16
2. Byers PH. Osteogenesis imperfecta. In: Royce PM, Steinmann B, editors. Connective tissue and its heritable disorders: molecular, genetic and medical aspects. New York: Wiley-Liss, 1993: 317-50
3. Steinmann B, Rao VH, Vogel A, Bruckner P, Gitzelmann R, Byers PH. Cysteine in the triple-helical domain of one allelic product of the a 1(1) gene of type I collagen produces a lethal form of osteogenesis imperfecta. J Biol Chem 1984; 259: 11129-38
4. Lund AM, Schwartz M, Raghunath M, Steinmann B, Skovby F. GIy802Asp substitution in the proa2(I) collagen chain in a family with recurrent osteogenesis imperfecta due to paternal mosaicism. Eur J Hum Genet 1996; 4: 39-45
5. Kielty CM, Hopkinson I, Grant ME. Collagen-the collagen family - structure, assembly, and organization in the extracellular matrix. In: Royce PM, Steinmann B, editors. Connective tissue and its heritable disorders: molecular, genetic and medical aspects. New York: WileyLiss, 1993: 103-47
6. Eriksen EF, Charles P, Meisen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type-I collagen formation and degradation in metabolic bone disease-correlation with bone histomorphometry. J Bone Miner Res 1993; 8: 127-32
7. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type-I collagen-a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635-40
8. Hertel NT, Stoltenberg M, Juul A, Main KM, Müller J, Nielsen CT, et al. Serum concentrations of type I and III procollagen propeptides in healthy children and girls with central precocious puberty during treatment with gonadotropin-releasing hormone analog and cyproterone acetate. J Clin Endocrinol Metab 1993; 76: 924-7
9. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity and stases of puberty. Arch Dis Child 1976; 51: 170-9
10. Orum O, Hansen M, Jensen CH, Sorensen HA, Jensen LB, HorslevPetersen K, Teisner B. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 1996; 19: 157-63
11. Kollerup G, Thamsborg G, Bhatia H, Sorensen OH. Quantitation of urinary hydroxypyridinium cross-links from collagen by highperformance liquid chromatography. Scand J Clin Lab Invest 1992; 52: 657-62
12. Petersen S, Sorensen HA, Kollerup GB, Beck Jensen J, Magid E. Evaluation of a new ELISA method for a serum osteocalcin and its clinical performance (Abstract). Bone 1995; 16: 217S
13. Proszynska K, Wieczorek E, Olszaniecka M, Lorenc RS. Collagen peptides in osteogenesis imperfecta, idiopathic juvenile osteoporosis and Ehlers-Danlos syndrome. Acta Paediatr 1996; 85: 688-91
14. Brenner RE, Schiller B, Vetter U, Ittner J, Teller WM. Serum concentrations of procollagen-I C-terminal propeptide, osteocalcin and insulin-like growth factor-I in patients with non-lethal osteogenesis imperfecta. Acta Paediatr 1993; 82: 764-7
15. Minisola S, Piccioni AL, Rosso R, Romagnoli E, Pacitti MT, Scarnecchia L, Mazzuoli G. Reduced serum levels of carboxyterminal propeptide of human type I procollagen in a family with type I-A osteogenesis imperfecta. Metabolism 1994; 43: 1261-5
16. Brenner RE, Vetter U, Bollen AM, Morike M, Eyre DR. Bone résorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. J Bone Miner Res 1994;9:993-7
17. Pasquali M, Still MJ, Dembure PP, Elsas LJ. Pyridinium cross-links in heritable disorders of collagen. Am J Hum Genet 1995; 57: 1508-10
18. Shapiro JR. Bone résorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta - Comment. J Bone Miner Res 1995; 10: 338-9
19. Melkko J, Hellevik T, Risteli L, Risteli J, Smedsrud B. Clearance of NH2-terminal propeptides of type I and III procollagen is a physiological function of the scavenger in liver endothelial cells. J Exp Med 1994; 179:405-12
20. Ste Marie LG, Charhon SA, Edouard C, Chapuy MC, Meunier PJ. Iliac bone histomorphometry in adults and children with osteogenesis imperfecta. J Clin Pathol 1984; 37: 1081-9
21. Baron R, Gertner JM, Lang R, Vignery A. Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda. PediatrRes 1983; 17: 204-7
22. Glorieux FH, Travers R, Chabot G, Lanove G. Bone histomorphometric analysis in osteogenesis imperfecta (Abstract). J Bone Miner Res 1994; 9 SuppI: A504
23. McCarthy EF, Earnest K, Rossiter K, Shapiro J. Bone histomorphometry in adults with type IA osteogenesis imperfecta. Clin Orthop Rel Res 1997; 254-62
24. Antoniazzi F, Bertoldo F, Mottes M, Valu M, Sirpresi S, Zamboni G, et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr 1996; 129: 432-9
25. Äström E, Söderhäll S. Beneficial effect of bisphosphonate during five years treatment of severe osteogenesis imperfecta. Acta Paediatr 1998; 87: 64-8